All Stories

Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect

The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi and Regeneron’s Dupixent remain unanswered.

Mar 10, 2025 - 11:42
 0
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi and Regeneron’s Dupixent remain unanswered.
Read More

Tags:

Previous Article

Russia the latest country to clamp down on Chinese imports

Next Article

3GW PV project on former coal mining land in China enters commercial operation

Related Posts

NIH cancels some grants for LGBTQ+ health research effective immediately: STAT

NIH cancels some grants for LGBTQ+ health research effe...

Mar 5, 2025  0

Fierce Biotech Layoff Tracker 2025: Atara halves workforce; BMS axes 223 jobs

Fierce Biotech Layoff Tracker 2025: Atara halves workfo...

Mar 4, 2025  0

ElevateBio gene therapy lowers levels of toxic protein in mice with Huntington's disease

ElevateBio gene therapy lowers levels of toxic protein ...

Feb 28, 2025  0